82 percent of variant carriers identified in exome sequencing had not undergone prior testing.
Almost 43% of those presenting to NCI center for second opinion have change in diagnosis.
Talazoparib, a poly(adenosine diphosphate-ribose) inhibitor, may significantly enhance progression-free survival in patients with advanced breast cancer and a germline BRCA1/2 mutation.
The FDA based its approval on the results of a triplet of phase 3 studies, the MONALEESA-2, MONALEESA-3, and MONALEESA-7.
For this phase 1b study, researchers enrolled 57 patients with ERBB2/HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane.
The North American Menopause Society has found that postmenopausal women with a breast cancer diagnosis may have vitamin D deficiency as well as higher rates of obesity.
Whole-exome sequencing revealed that PALB2, ATM, CHEK2, and MSH6 genes were significantly associated with an increased risk of breast cancer; MSH6, RAD51C, TP53, and ATM were found to be linked to an increased risk of ovarian cancer.
Although endocrine therapy following surgery is recommended for HR-positive/HER2-negative, axillary node-negative breast cancers, the value of adjuvant chemotherapy in the setting of moderate risk is unclear.
Lumpectomy, radiotherapy tied to reduction in breast cancer mortality vs lumpectomy, mastectomy.
C-509T allele and postoperative cosmetic surgery significantly linked to breast fibrosis risk.
No increased risk of corpus uteri, invasive breast cancer for women undergoing assisted reproduction.
Ribociclib approved in combo with AI as endocrine tx for HR-positive, HER2-negative advanced breast CA.
Investigators report results from the MONALEESA-7 trial, which assessed ribociclib plus endocrine therapy in premenopausal women with advanced breast cancer.
In year 1, 13% did not undergo MRI or mammography; up to 19% by year 5.
Computer analysis is not better than human clinical evaluation when it comes to measuring breast densityMay 03, 2018
Similar associations were observed with clinical BI-RADS and automated BI-RADS with respect to interval and screen-detected cancer.
A multi-analyte blood test, CancerSEEK, can detect 8 common cancer types, with high sensitivity and specificity.
Both patients with and without BRCA mutations have comparable survival rates.
For women who work night shifts, breast cancer risks increase by 3.3% for every 5 years of work.
Breast cancer diagnosis is higher among women who currently use or recently used contemporary hormonal contraceptives than among women who have never used hormonal contraceptives.
Consensus regarding mammography screening varies, and conflicting guidelines from medical organizations can cause confusion for patients and providers.
A variety of non-hormone options and therapies are available for treatment of estrogen-depletion symptoms and clinical problems after a diagnosis of breast cancer.
Thousands of US lives would be saved each year if women received annual mammograms starting at age 40.
Breast cancer risk is increased with a larger number of first- and second-degree relatives diagnosed as having breast cancer for both BRCA1/BRCA2 carriers.
A breast cancer screening program helped improve mammography referral and screening rates in a federally qualified health center.
Drinking the equivalent of a small glass of wine or beer a day increases pre-menopausal breast cancer risk by 5% and post-menopausal breast cancer risk by 9%.
Developing breast cancer was associated inversely with taking 3 or more tablets of low-dose aspirin per week.
Evidence supports the routine use of mind-body practices, such as yoga, meditation, relaxation techniques, and passive music therapy, to address common mental health concerns in patients with breast cancer.
Nearly 70% of participants who self-administered acupressure therapy experienced improved levels of fatigue.
As breast cancer survivorship increases, NPs have taken on long-term patient care.
Extending adjuvant aromatase inhibitor treatment can decrease disease recurrence and increase survival in breast cancer patients.